Stoke Therapeutics Inc

For the period ended Sep 30, 2024. Filed Nov 5, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 5, 2024

STOK$27.21-1.8%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated statements of stockholders’ equity

Common Stock · Additionalpaid-in capital · Accumulated other comprehensive gain (loss) · Accumulateddeficit · Total stockholders’equity
Shares · Amount
Balance as of December 31, 2022	39,439,575	$4	$483,170		$(1,175)		$(297,150)		$184,849
Net loss	—	—	—		—		(22,545)		(22,545)
Unrealized gain on marketable securities	—	—	—		577		—		577
Stock-based compensation	—	—	5,887		—		—		5,887
Issuance of common stock upon exercise of stock options	80,611	—	158		—		—		158
Issuance of common stock related to employee stock purchase plan	19,550	—	153		—		—		153
Shares sold as part of controlled equity offering sales agreement	4,635,353	—	44,743		—		—		44,743
Balance as of March 31, 2023	44,175,089	$4	$534,111		$(598)		$(319,695)		$213,822
Net loss	—	—	—		—		(30,654)		(30,654)
Unrealized gain on marketable securities	—	—	—		219		—		219
Stock-based compensation	—	—	6,760		—		—		6,760
Issuance of common stock upon exercise of stock options	27,908	—	48		—		—		48
Balance as of June 30, 2023	44,202,997	$4	$540,919		$(379)		$(350,349)		$190,195
Net loss	—	—	—		—		(24,542)		(24,542)
Unrealized gain on marketable securities	—	—	—		232		—		232
Stock-based compensation	—	—	6,552		—		—		6,552
Issuance of common stock upon exercise of stock options	38,197	—	161		—		—		161
Issuance of common stock related to employee stock purchase plan	51,921	—	401		—		—		401
Shares sold as part of controlled equity offering sales agreement	—	—		—		—		—
Balance as of September 30, 2023	44,293,115	$4	$548,033		$(147)		$(374,891)		$172,999
Balance as of December 31, 2023	45,918,233	$5	$561,433		$(24)		$(401,849)		$159,565
Net loss	—	—	—		—		(26,374)		(26,374)
Unrealized gain on marketable securities	—	—	—		24		—		24
Stock-based compensation	—	—	5,410		—		—		5,410
Issuance of common stock upon exercise of stock options	270,032	—	250		—		—		250
Issuance of common stock related to employee stock purchase plan	37,542	—	168		—		—		168
Shares sold as part of controlled equity offering sales agreement	272,270	—	1,299		—		—		1,299
Balance as of March 31, 2024	46,498,077	$5	$568,560		$—		$(428,223)		$140,342
Net loss	—	—	—		—		(25,695)		(25,695)
Unrealized gain on marketable securities	—	—	—		(15)		—		(15)
Stock-based compensation	—	—	7,427		—		—		7,427
Issuance of common stock upon exercise of stock options	252,007	—	766		—		—		766
Issuance of common stock and warrants upon follow-on offering, net of underwriting discounts, commissions and offering costs	5,555,557	—	119,884		—		—		119,884
Balance as of June 30, 2024	52,305,641	$5	$696,637		$(15)		$(453,918)		$242,709
Net loss	—	—	—		—		(26,430)		(26,430)
Unrealized gain on marketable securities	—	—	—		181		—		181
Stock-based compensation	—	—	7,494		—		—		7,494
Issuance of common stock upon exercise of stock options	52,751	—	139		—		—		139
Issuance of common stock related to employee stock purchase plan	73,099	—	364		—		—		364
Shares sold as part of controlled equity offering sales agreement	509,700	—	7,656		—		—		7,656
Balance as of September 30, 2024	52,941,191	$5	$712,290		$166		$(480,348)		$232,113

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.